Last reviewed · How we verify
High Dose Enoxaparin
High Dose Enoxaparin is a Low-molecular-weight heparin (LMWH) Small molecule drug developed by Oregon Health and Science University. It is currently FDA-approved for Acute coronary syndrome, Deep vein thrombosis prophylaxis and treatment, Pulmonary embolism treatment. Also known as: Lovenox.
High-dose enoxaparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa.
High-dose enoxaparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa. Used for Acute coronary syndrome, Deep vein thrombosis prophylaxis and treatment, Pulmonary embolism treatment.
At a glance
| Generic name | High Dose Enoxaparin |
|---|---|
| Also known as | Lovenox |
| Sponsor | Oregon Health and Science University |
| Drug class | Low-molecular-weight heparin (LMWH) |
| Target | Coagulation factors Xa and IIa (via antithrombin III) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Enoxaparin is a low-molecular-weight heparin (LMWH) derived from unfractionated heparin. It works by potentiating antithrombin III, which inactivates coagulation factors Xa and IIa, thereby preventing thrombus formation. High-dose formulations are used in acute thrombotic conditions requiring more intensive anticoagulation.
Approved indications
- Acute coronary syndrome
- Deep vein thrombosis prophylaxis and treatment
- Pulmonary embolism treatment
- Unstable angina
Common side effects
- Bleeding
- Thrombocytopenia
- Injection site hematoma
- Elevated transaminases
Key clinical trials
- A Clinical Study of SHR-2004 Injection in Preventing Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty (PHASE3)
- A Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing TKA (PHASE2)
- STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis (PHASE4)
- Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies (PHASE2, PHASE3)
- Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care (PHASE3)
- SHR-2004 for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty (PHASE2)
- Individual Dose Adjustment of Low-molecular-weight-heparin by Thromodynamics Test. (PHASE4)
- Comparison of the Risk of Venous Thromboembolism (i.e., Blood Clots in the Veins) and Bleeding Events in a Population of Obese Patients Receiving Higher-Dose or Extended-Duration Versus Conventional-Dose or Conventional-Duration of Prophylaxis (i.e., Preventive Treatment) With Enoxaparin
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- High Dose Enoxaparin CI brief — competitive landscape report
- High Dose Enoxaparin updates RSS · CI watch RSS
- Oregon Health and Science University portfolio CI
Frequently asked questions about High Dose Enoxaparin
What is High Dose Enoxaparin?
How does High Dose Enoxaparin work?
What is High Dose Enoxaparin used for?
Who makes High Dose Enoxaparin?
Is High Dose Enoxaparin also known as anything else?
What drug class is High Dose Enoxaparin in?
What development phase is High Dose Enoxaparin in?
What are the side effects of High Dose Enoxaparin?
What does High Dose Enoxaparin target?
Related
- Drug class: All Low-molecular-weight heparin (LMWH) drugs
- Target: All drugs targeting Coagulation factors Xa and IIa (via antithrombin III)
- Manufacturer: Oregon Health and Science University — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Acute coronary syndrome
- Indication: Drugs for Deep vein thrombosis prophylaxis and treatment
- Indication: Drugs for Pulmonary embolism treatment
- Also known as: Lovenox
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing